United Therapeutics Corporation officer Paul Mahon filed a Form 144 notice of proposed sale on November 19, 2026, covering 8,300 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services.
Key Highlights
- Proposed sale: 8,300 shares of United Therapeutics common stock with an aggregate market value of $4,690,228.74, according to the filing.
- Acquisition method: The shares were acquired on November 19, 2026, via a stock option exercise from the issuer, with payment made in cash.
- Shares outstanding: The filing lists 42,588,726 shares of common stock outstanding at the time of notice.
- Trading plan: The filing indicates a Rule 10b5-1 plan was adopted on August 11, 2025.
- Prior sales in past 3 months: The filing discloses six prior sales of 8,300 shares each, dating back to August 20, 2026, with gross proceeds ranging from $4,000,836.55 to $4,968,932.78 per transaction.
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the executing broker.
Paul Mahon's Proposed Stock Sale Under Rule 144 at United Therapeutics
Paul Mahon, identified in the filing as an officer of United Therapeutics Corporation (NASDAQ:UTHR), filed a Form 144 notice on November 19, 2026, disclosing a proposed sale of 8,300 shares of the company's common stock. The aggregate market value of the proposed sale is listed as $4,690,228.74. The shares were acquired on the same date through a stock option exercise from the issuer, with the full purchase price paid in cash, according to the filing.
The filing indicates that Mahon is relying on Rule 10b5-1, with a written trading plan adoption date of August 11, 2025. The notice covers securities to be sold on the NASDAQ exchange through Morgan Stanley Smith Barney LLC Executive Financial Services. As of the filing date, the total shares of United Therapeutics common stock outstanding are reported as 42,588,726.
In addition, the filing discloses six prior sales of common stock by Mahon over the preceding three months. Each of those transactions also involved 8,300 shares, with dates of August 20, September 3, September 17, October 1, October 15, and November 5, 2026, and gross proceeds of $4,342,078.81, $4,000,836.55, $4,129,607.73, $4,689,050.97, $4,517,709.09, and $4,968,932.78, respectively, as stated in the filing. United Therapeutics is headquartered at 1000 Spring Street, Silver Spring, Maryland 20910, according to the issuer information section of the notice.
What Was Disclosed
The Form 144 filing by officer Paul Mahon discloses a proposed sale of 8,300 United Therapeutics common shares acquired via stock option exercise, with an aggregate market value of $4,690,228.74, under a Rule 10b5-1 plan adopted August 11, 2025.




Please wait processing your request...